Is Autonomy the Key to Unlocking the Potential of Drones?

Both pilots and companies are navigating a thin line between security and innovation. Host Grant Guillot talks with leaders, influencers, and experts across the drone industry to guide us through the complex web of technology and policy in the United States.

 

What’s one of the biggest hurdles to scaling drones for delivery and other applications? Managing the sky is the answer. Discussing unmanned traffic management (UTM), Drones in America host Grant Guillot spoke with Eyal Zor, CEO of Airwayz. Airwayz delivers technology solutions to manage real-time multi-drone flight performance leveraging software-based AI.

Zor founded the company with two other partners, all Israeli Air Force veterans. “The objective is to manage the unique airspace for the drone economy,” Zor said.

“The test showed how managing traffic in real-time would look, considering safety and efficiency” – Eyal Zor

With drone technology advanced, UTM is the missing piece for scalability. “We focus on a solution for mass drones in a given area for delivery, security, or other applications. It’s not unlike traditional aviation and managing multiple air vehicles. UTM is building the road for air delivery,” Zor noted.

One of the most exciting contributions by Airwayz was participating in a multi-drone test in March. The Israeli town of Hadera was the location for testing a hive of delivery drones from a central control room using Airwayz software. The trial included coordinating unmanned aircraft as well as planes and helicopters. It was one of the largest drone experiments ever conducted. “The test showed how managing traffic in real-time would look, considering safety and efficiency,” Zor said.

The test will fuel the future of drone usage, and AI will become critical in scaling drone delivery with a working model. “The benefits of AI are at decision points along with data analysis to find the most efficient ways to execute,” Zor added.

See Previous Episodes of Drones In America Here

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More